Iterative structure-based improvement of a fusion-glycoprotein vaccine against RSV.
Joyce, M.G., Zhang, B., Ou, L., Chen, M., Chuang, G.Y., Druz, A., Kong, W.P., Lai, Y.T., Rundlet, E.J., Tsybovsky, Y., Yang, Y., Georgiev, I.S., Guttman, M., Lees, C.R., Pancera, M., Sastry, M., Soto, C., Stewart-Jones, G.B., Thomas, P.V., Van Galen, J.G., Baxa, U., Lee, K.K., Mascola, J.R., Graham, B.S., Kwong, P.D.(2016) Nat Struct Mol Biol 23: 811-820
- PubMed: 27478931 
- DOI: 10.1038/nsmb.3267
- Primary Citation of Related Structures:  
5K6B, 5K6C, 5K6F, 5K6G, 5K6H, 5K6I - PubMed Abstract: 
Structure-based design of vaccines, particularly the iterative optimization used so successfully in the structure-based design of drugs, has been a long-sought goal. We previously developed a first-generation vaccine antigen called DS-Cav1, comprising a prefusion-stabilized form of the fusion (F) glycoprotein, which elicits high-titer protective responses against respiratory syncytial virus (RSV) in mice and macaques ...